Human Anti-ERBB3 Recombinant Antibody (TAB-189)

Customer Review

There are currently no Customer reviews or questions for TAB-189. Click the button above to contact us or submit your feedback about this product.

Michael White
20.Aug,23

Excellent for ERBB3 Research

The Anti-ERBB3 Recombinant Antibody has been excellent for our ERBB3 studies. Its specificity and sensitivity are outstanding, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Laura Scott
04.Nov,22

Effective and Dependable

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for ERBB3 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Brian Young
28.Jun,21

Consistent High-Quality Results

This antibody has proven to be consistent and dependable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for ERBB3 have been particularly beneficial.

Q&As

1. Is the anti-ERBB3 recombinant antibody suitable for use in Western blotting?

   A: Yes, the anti-ERBB3 recombinant antibody (TAB-189) is suitable for use in Western blotting. It provides specific binding to ERBB3, allowing for reliable detection in Western blot assays.

2. What are the recommended storage conditions for the anti-ERBB3 recombinant antibody?

   A: The recommended storage condition for the anti-ERBB3 recombinant antibody (TAB-189) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-ERBB3 recombinant antibody be used in immunoprecipitation assays?

   A: Yes, the anti-ERBB3 recombinant antibody (TAB-189) can be used in immunoprecipitation assays. It provides specific binding to ERBB3, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-ERBB3 recombinant antibody effective in ELISA applications?

   A: Yes, the anti-ERBB3 recombinant antibody (TAB-189) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of ERBB3.

5. What is the optimal dilution for using the anti-ERBB3 recombinant antibody in immunofluorescence?

   A: The optimal dilution for using the anti-ERBB3 recombinant antibody (TAB-189) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Shorstova, Tatiana, et al. "Reprogramming of nucleotide metabolism mediates synergy between epigenetic therapy and MAP kinase inhibition." Molecular Cancer Therapeutics 20.1 (2021): 64-75. https://doi.org/10.1158/1535-7163.MCT-20-0259
   This study investigates the synergy between epigenetic therapy using BET inhibitors (BETi) and MAP kinase inhibitors (MEKi) in treating small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), and other ovarian cancer subtypes. The researchers identified that combining the BET inhibitor OTX015 with MEK inhibitors cobimetinib and trametinib significantly represses the proliferation of SCCOHT both in vitro and in vivo. Mass spectrometry revealed that this combination therapy downregulates proteins involved in nucleotide metabolism, leading to reduced pools of nucleotide metabolites and subsequent cell-cycle arrest. This indicates that dual treatment with BETi and MEKi could be an effective therapeutic strategy against SCCOHT and other resistant ovarian cancers.
   Creative Biolabs provided patritumab (anti-HER3 antibody, Cat# TAB-189), which was used to test the effects of targeting HER3 in combination with BETi in the ovarian cancer models. The inclusion of patritumab in the study was crucial for exploring the potential synergy between BET inhibitors and HER3 pathway inhibition. This helped to delineate the specificity and efficacy of the combined treatment strategies, thereby supporting the study's aim of identifying effective combination therapies for challenging ovarian cancer subtypes.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-189, RRID: AB_3111858)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Related Diseases

EGFR Tyrosine Kinase Inhibitor Resistance

Related Signaling Pathways

ErbB Signaling Pathway

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "ERBB3"

Select a product category from the dropdown menu below to view related products.